The HAPO study recently demonstrated that no specific threshold for the risk of adverse events for both mother and child associated with GDM can be set as the risk increase is continuous[11]. Other studies[12-14] have supported the idea of lowering the diagnostic threshold in the diagnostic criteria for GDM, taking the maternal and foetal risks of hyperglycemia into consideration. In 2010 the IADPSG outlined new diagnostic criteria for GDM[15] based on the knowledge achieved in the HAPO study. This new guideline from IADPSG was adopted by the WHO in 2013[16] and ADA in 2014[8] and is based on the risk of adverse pregnancy outcomes As shown in Table 1 the threshold for a positive test is exceedance of one of the following three plasma glucoses; fasting plasma glucose ≥ 5.1 mmol/L (≥ 92 mg/dL), 1 h ≥ 10.0 mmol/L (180 mg/dL), or 2 h ≥ 8.5 mmol/L (153 mg/dL)[15]. In comparison the WHO recommended threshold in 1999 was fasting plasma glucose ≥ 7.0 mmol/L (126 mg/dL) and in 1985 fasting plasma glucose ≥ 7.8 mmol/L (140 mg/dL)[6].